DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus

GV-TH-01, a Phase 1 open-label trial of a DNA prime—Modified Vaccinia Ankara (MVA) boost vaccine (GOVX-B11), was undertaken in HIV infected participants on antiretroviral treatment (ART) to evaluate safety and vaccine-elicited T cell responses, and explore the ability of elicited CD8+ T cells to con...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2016-10, Vol.11 (10), p.e0163164
Hauptverfasser:	Thompson, Melanie, Heath, Sonya L, Sweeton, Bentley, Williams, Kathy, Cunningham, Pamela, Keele, Brandon F, Sen, Sharon, Palmer, Brent E, Chomont, Nicolas, Xu, Yongxian, Basu, Rahul, Hellerstein, Michael S, Kwa, Suefen, Robinson, Harriet L
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired immune deficiency syndrome Adult AIDS AIDS vaccines Anti-HIV Agents - pharmacology Anti-HIV Agents - therapeutic use Antiretroviral agents Antiretroviral drugs Antiretroviral therapy Biology and Life Sciences CD4 antigen CD4-Positive T-Lymphocytes - cytology CD4-Positive T-Lymphocytes - drug effects CD4-Positive T-Lymphocytes - immunology CD4-Positive T-Lymphocytes - metabolism CD8 antigen CD8-Positive T-Lymphocytes - cytology CD8-Positive T-Lymphocytes - drug effects CD8-Positive T-Lymphocytes - immunology CD8-Positive T-Lymphocytes - metabolism Cell Count Deoxyribonucleic acid Disease resistance DNA DNA vaccines Emergence Epitopes Exhaustion Female Gag protein Gene Products, gag - metabolism Health aspects Highly active antiretroviral therapy HIV HIV Infections - drug therapy HIV Infections - immunology HIV Infections - prevention & control HIV-1 - drug effects HIV-1 - immunology HIV-1 - physiology Human immunodeficiency virus Humans Immune response Immunization, Secondary - adverse effects Immunization, Secondary - methods Interruption Lymphocytes Lymphocytes T Male Medicine and Health Sciences Mutation Peptides Quality Recurrence Research and Analysis Methods Ribonucleic acid RNA Safety Seroconversion Species Specificity T cells Therapy Traffic control Vaccination Vaccination - adverse effects Vaccination - methods Vaccines Vaccines, DNA - immunology Vaccinia Viral Load - drug effects Viral Load - immunology Viremia Viruses Withholding Treatment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	GV-TH-01, a Phase 1 open-label trial of a DNA prime—Modified Vaccinia Ankara (MVA) boost vaccine (GOVX-B11), was undertaken in HIV infected participants on antiretroviral treatment (ART) to evaluate safety and vaccine-elicited T cell responses, and explore the ability of elicited CD8+ T cells to control viral rebound during analytical treatment interruption (TI). Nine men who began antiretroviral therapy (ART) within 18 months of seroconversion and had sustained plasma HIV-1 RNA
ISSN:	1932-6203 1932-6203
DOI:	10.1371/journal.pone.0163164